SWIPP is currently owned by its two co-founders Christer Sjögren and Bengt Westrin, AdhexPharma (France) and 14 Swedish investors. SWIPP AB is at present a private limited company and its shares are not traded publicly. The company currently has 17 owners. In the most recent new share issue (Oct 2021) 15 of the 17 owners participated. The CEO and all the Board members are, through companies, co-owners of SWIPP, and they all participated in the most recent new share issue.

In order for the company’s projects to achieve optimal commercial outcomes for sale and out-licensing, additional injections of capital are required. SWIPP’s intention is to fill these needs with the help of existing owners and a few selected, new investors. An IPO is currently not planned. The company’s financial plans, like its other plans, may change depending on both internal and external factors.

Owners in SWIPP

After four years as a strategy consultant at A.T. Kearney, Bruno Loiseau joined Burgundy Ventures Group in 2005 and helped to found AdhexPharma, which subsequently acquired Solvay Pharmaceuticals’ transdermal products. With Bruno as Managing Director, AdhexPharma has seen annual growth of more than 30% since 2007, has registered four new medicinal products as a CDMO, and is currently developing a number of oral films and transdermal patches. AdhexPharma is part of Adhex Group, which has sales in excess of MEUR 130 and approx. 650 employees. Bruno has an MBA from ESSEC Business School and is a French citizen.

About AdhexPharma: Contract manufacturer of medical films and patches, with a manufacturing site outside Dijon, France. Together with its larger sister company Adhex Technologies, AdhexPharma has sales in excess of MEUR 130 and has 650 employees. It is owned by Burgundy Ventures Holding Group, which is controlled by the businessman Roland de la Brosse.

Christer Sjögren is a Doctor of Veterinary Medicine (DVM), has a PhD, and was Associate Professor of pharmacology at The Royal Veterinary College (Kungliga Veterinärhögskolan) until 1975. Christer is also a former consulting professor in experimental obstetrics and gynaecology at Uppsala University. He has more than 45 years’ experience from senior operational management positions at big pharma companies, including Pharmacia and Novo Nordisk, and from similar positions and Board seats at smaller companies, such as Perstorp Pharma, LIDDS AB, Peptonic Medical AB and Juvantia Pharma OY. Christer has also held senior positions at the clinical contract research organisations Quintiles and CDC, has chaired the working group for Clinical Operations and Regulatory Affairs at the industry association SwedenBIO, and has been a board member of VINNOVA’s industry research programme SAMBIO. 

Bengt Westrin has over 30 years’ experience from the life science industry, ranging from start-ups to big pharma companies, and areas ranging from product development and regulatory affairs to project management and business development.

Prior to SWIPP he was CEO at CombiGene AB, AcuCort AB, Idogen AB and Lipopeptide AB, as well as VP Business Development at Camurus AB. Bengt has also carried out numerous consulting assignments for various companies and public organisations. He has an MSc in Chemical Engineering and a PhD from LTH at Lund University, where he has also been an honorary Associate Professor since 1999. During his time at AcuCort AB, he laid the groundwork for what is now an approved oral film product: Isicort® (dexamethasone) for the treatment of acute allergic reactions, croup, chemotherapy-induced nausea and vomiting, and is also approved for the treatment of Covid-19 patients. Bengt Westrin is named inventor on three patent applications in the film field. 

Håkan Lagerberg is a Swedish investor, business developer and business leader. He is CEO and co-owner of Swedencare AB (publ) and is a board member at Polygiene AB, as well as an investor in a number of listed and private companies. 

Rolf Abdon founded Abdon Finax AB and Grain Millers Inc (USA). Member of the Advisory Council for the INSEAD Business School in Fontainebleau, France.

Johan Säfholm graduated with an MSc in Applied Physics from Linköping University in 2003. Since then, he has gained international experience in the development and manufacture of consumer electronics in a variety of roles as team leader and product manager. Johan has worked at Sony Ericsson, ST-Ericsson, Axis and Flatfrog, companies with between 40 and 5,000 employees and a global presence. He also co-founded Swed Ventures AB and is a board member at Avsalt AB. 

About Annette Säfholm: CEO at Gedea Biotech AB, former Head of Communication & Project Management at Idogen AB (publ), and a co-founder of WNTresearch AB (publ).

Lars Persson has worked as an investment manager at Industrifonden, among other roles, and has been CEO at Almi Invest Syd. Chairman of the Board at BoMill AB (publ) and a board member at Invent Medic Sweden AB (publ), Triomed AB and Coegin Pharma AB (publ).

Lars Hedbys has extensive experience from the science industry, including various positions at AstraZeneca, where he worked at vice president level in the research organisation. He has also co-founded a number of companies and has served as CEO at several Swedish and international companies. 

Anders Carlsson is involved in early pharmaceutical development through his consultancy company MediGelium AB. He has many years of experience in successfully developing innovative formulations for both existing and novel pharmaceuticals for preclinical and clinical trials. Anders also co-founded Lipidor AB (publ) and was formerly its CEO.

Torgny Hellström is a business consultant with more than 30 years’ experience from the tech sector. He is Chairman of the Board at Precise Biometrics AB (publ), Starbreeze AB (publ) and Drupps Group AB. Torgny’s previous assignments include a number of Board and CEO positions at listed companies, and senior management positions with large tech companies, e.g. Ericsson. Torgny has a Master of Laws (LL.M.) from Stockholm University.